Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
Air Liquide will provide care for people living with respiratory diseases such as chronic obstructive pulmonary disease (COPD) and sleep apnea
Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
BIL also holds an option to increase its equity stake by an additional 15%
The expansion, supported by a significant UK government grant, includes a new lipid system synthesis facility and enhanced R&D capabilities
Ultra-high purity surfactant for biologics and parenteral drug formulations
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Subscribe To Our Newsletter & Stay Updated
